Published on : Jun 10, 2016
ALBANY, New York, June 10, 2016: ResearchMoz.us has announced the addition of the “Short Bowel Syndrome - Market Insights, Epidemiology and Market Forecast-2020” report to its offering. This report presents an extensive analysis on the therapeutics in the short bowel syndrome market and also entails an analysis on the current and future competitive dynamics of the market. The report also presents a thorough review of the key factors stimulating as well as inhibiting the growth of the market. In addition, the key trends, prime opportunities, and unmet needs within this market in the forecast period from 2015 to 2020 have also been analyzed in this report.
The study also helps in the development of both in-licensing and out-licensing strategies by encapsulating a review of the marketed drugs and other products in the market for short bowel syndrome. It also helps in identifying the prime companies that have the most promising pipelines. The report also presents the size of the market in regions such as the U.S. and EU5 countries, including , France, Spain, the UK, and Italy, and the Rest of the World (RoW).
As per the report, the global market for short bowel syndrome therapeutics is predicted to reach US$2.7 bn by 2020. The total population having short bowel syndrome will expand at a 1.73% CAGR between 2015 and 2020. The report starts by presenting a disease overview, under which information has been presented on the symptoms, diagnosis, etiology, and treatment of this disease. Short bowel syndrome is a disorder in which malabsorption takes place in the body owing to the surgical removal of more than two thirds of the small intestine. It can rarely also occur owing to acute dysfunction of a big segment of the bowel. The majority of the cases are acquired, however, some infants are born with a congenital short bowel.
Click here to get more info with TOC in a PDF Format: https://www.researchmoz.us/enquiry.php?type=S&repid=720127
In the following section of the report, the pharmacokinetics properties and mechanism of action of marketed drugs in the short bowel syndrome therapeutics market have been described. As stated in the report, the treatment of short bowel syndrome is complex and there are a number of treatment options available. The plan of treatment is usually customized and may include total parenteral nutrition (TPN) support, which comprises parenteral nutrition, enteral nutrition, and oral rehydration solutions. At present, Gattex (tedugludtide) has emerged as the first non-surgical treatment option for short bowel syndrome. It is approved by the U.S. FDA and is poised to enhance the living condition of patients suffering from this disorder.
In the last section of the report, the geographical segmentation of the market has been presented. This section entails the size of the market in Germany, the UK, the U.S, France, Italy, Japan, Spain, and Rest of the World (RoW) from 2011 to 2014 and the forecasted size of the market in these countries from 2015 to 2020.
To order report Call USA – Canada Toll Free: 866-997-4948 or send an email on firstname.lastname@example.org